News

All

May 2, 2013

On our way to the INTA Annual Meeting

On our way to the INTA Annual Meeting The partners and trademark attorneys Elisabeth Kasznar Fekete, Eduardo Colonna Rosman, Rafael Lacaz Amaral and Liz Starling, besides the foreign trademark coordinator Monica Simas Medeiros, will attend the 135th Annual Meeting of the International Trademark Association (INTA), to be held in Dallas, Texas, from May 4th to the 8th.

Ler notícia

May 1, 2013

Avoiding lengthy litigation

Brazil IP FOCUS – Managing IP Magazine – May 2013 edition

Generally, when IP rights holders decide to file a law suit in Brazil, they are looking for a swift answer to the violation of their rights. It is widely known, however, that law suits in Brazil usually take a long time to reach a final outcome. This is especially true in infringement and nullity actions involving patent rights, due to the technical background knowledge demanded to fully understand the technology at issue (in most of these law suits an expert is nominated by the trial judge to assist in clarifying technical aspects of the case). That is why injunctive relief plays an important role in litigation cases, as it is an efficient measure to put a stop to the infringement of IP rights while a final decision is being rendered in the case.

Ler notícia

May 1, 2013

El rol de la Agencia Nacional de Vigilancia Sanitaria en la concesión de patentes de fármacos en Brasil: una cuestión todavía polémica

INTRODUCCIÓN: EL INSTITUTO DE LA PREVIA ANUENCIA Y LOS DILEMAS QUE LO MISMO HA GENERADO.

Pasados dieciséis años de la promulgación de la Ley Brasileña de Propiedad Industrial (Ley nº 9.279/1996), la cual introdujo en el ordenamiento jurídico brasileño las reglas establecidas en el Acuerdo sobre los Aspectos de los Derechos de Propiedad Intelectual Relacionados con el Comercio (ADPIC), una de las cuestiones jurídicas más polémicas que se coloca cuanto a su interpretación sigue todavía sin solución: ¿cuál debe ser el rol de la Agencia Nacional de Vigilancia Sanitaria (ANVISA, en el acrónimo portugués) en la concesión de patentes de fármacos? Tal pregunta se hace respeto a la correcta interpretación del artículo 229-C de la Ley nº 9.279/1996, que a la letra señala:

Ler notícia

May 1, 2013

Winds of Change: Intellectual Property and Wind Power – Why the Brazilian Market Can Become Attractive

INTRODUCTION

Global energy demand continues to increase, with major developing countries acting as the main driving force behind such rise. However, the world energy balance is still highly dependent on the finite source of fossil fuels, which is considered to be the major responsible for atmosphere pollution in big cities. Furthermore, the long term consequences of the use of these non-renewable fuel sources are still unknown. Global warming, for example, is pointed out to be one of its most undesirable effects.

In this scenario, the need to diversify the energy matrix using more renewable energy sources has become urgent. One of the most triumphant clean energy sources that has been developed in the last years is wind power. The installed wind power capacity is increasing significantly worldwide as well as its importance to the

  • ...
Ler notícia

April 13, 2013

Newsletter 2013.02 – Recent developments regarding examination of pharma patent applications

Brazilian PTO’s new Resolution No. 80 of March 19, 2013 sets forth rules for granting priority examination for patent applications related to pharmaceutical products and processes, and equipments and materials related to public health

The Brazilian PTO published Resolution No. 80, on March 19, 2013 in the Official Gazette, which establishes the proceedings for requesting priority examination of patent applications related to pharmaceutical products and processes, and equipments and materials related to public health. We are pleased to hereby enclose a complete English language version of the resolution for your review.

According to the new resolution, now in full force, priority for the examination of patent applications related to public health may be requested by:
(i) The Ministry of Health when the object of the patent is considered strategic to the policies within the National Public Health System (the SUS) — the possibility of having a

Ler notícia

February 5, 2013

Concepts and protection involving famous marks in Brazil

Managing IP Magazine – March 2013

 

Fame

Depending on the degree of reputation or recognition of the mark, it may be qualified as WELL-KNOWN or HIGLY REPUTED (widely recognized by the general consuming public; well-known to the public at large), being protected under different levels.

Legal protection to well-known marks

WELL-KNOWN marks in the form of Article 6bis of CUP are protected under the Brazilian IP Law against imitation or reproduction in the same or related market segment. Pre-existence of a regular application or registration is not a condition to seek the protection. Being this an exception to the first-to-file rule in force in Brazil, the Brazilian Law requires that the Opponent files an application for its own mark in order to enforce the special protection.

  • ...
Ler notícia

December 1, 2012

Newsletter 2012.12 – New draft guidelines for patent applications in the biotechnology field

The Brazilian Patent amp; Trademark Office (PTO) has recently opened a new Public Consultation, this time on the draft guidelines for the examination of patent applications in the biotechnology field. The Public Consultation was published in the Federal Official Gazette on December 5, 2012 and any interested party may make their submissions within a 60-day-term counted as from that publication date.

The new draft provides more definitions and illustrations on biotech subject matter not expressly mentioned in Law # 9,279/96 (ESTs, primers, SNPs, cDNAs, ORFs, fusion proteins, etc.), indicating whether they would patentable or not in view of the main statutory prohibitions found in articles 10, (IX) and 18, (I) and (III) of that Law.

  • Kasznar Leonardos
  • Ler notícia

    November 3, 2012

    Newsletter 2012.11 – Brazilian Patent Office shall reject patent applications on genetic use restriction technologies

    Operational Rule No. 005/2012 was issued by the Brazilian Patent Office on October 30, 2012, ruling on the interference of the Biosafety Law (No No. 11,105 of 24 March 2005) on the granting of Biotechnology patent applications.

    This operational rule came as a consequence of previous Brazilian Patent Office's Notification No. 0182-2012-AGU-PGF/INPI/COOPI-ALB-2.2, published on August 21, 2012 in Official Gazette No. 2,172, which considered not to be patentable subject-matter involving genetic use restriction technologies (GURTs) for plants, as set forth by the Biosafety Law (BL).

    This BL establishes, in its Section 6º VII, that it is forbidden to: “use, sell register, patent and license genetic use restriction technologies”, these technologies being defined in the sole paragraph of said section as “any process by which human intervention generates or multiplies genetically modified plants to produce sterile reproductive structures, as well as any manner of genetic manipulation that aims a

  • Kasznar Leonardos
  • Ler notícia

    November 2, 2012

    Newsletter 2012.10 – Proposal of changes on Brazilian FDA’s Resolution RDC #45 dated 2008, which regulates the administrative proceedings for prior consent analysis

    The Brazilian FDA (ANVISA) has offered, for public consultation, a proposal of a new resolution relative to the prior consent proceedings applied to applications encompassing pharmaceutical products and processes, as set forth in Section 229-C of the Brazilian IP Law.

    This Public Consultation #66 was published in the Official Federal Gazette on October 16, 2012, opening a 60-day term for submission of any comments/suggestions on the changes in the examination procedures that will proposedly be applied by ANVISA in the future. Such term of 60 days started on October 24, 2012, when the proposal actually became available to the public, so that anyone is able to make comments and criticize the proposal up to December 22, 2012.,/pgt;

    This comes in consequence to previous opinions raised by the Brazilian Federal Attorneyship (AGU) which stated that, upon complying with the dispositions of Section 229-C, ANVISA should limit their analysis to public health factors and should not examine the app

  • Kasznar Leonardos
  • Ler notícia

    November 1, 2012

    Newsletter 2012.09 – The Brazilian Patent and Trademark Office (BPTO) publishes new resolution also ruling on applicability of PCT Rule 49.6 for Brazil

    New Resolution No. 291 published by the BPTO on September 4, 2012 establishes new proceedings for nationalizing, in Brazil, applications filed under the PCT ? Patent Cooperation Treaty ? following Rule 49.6 of such treaty.

    Rule 49.6 sets forth that the applicant may reinstate the rights after failure to timely enter the national phase, provided that this failure was unintentional or occurred in spite of due care required by the circumstances having been taken.

    The major change introduced by this Resolution is the establishment of the procedures applied concerning PCT Rule 49.6, thus including the possibility of reinstating the rights of the applicant with respect to the national phase entry, if the delay in meeting the 30

  • Kasznar Leonardos
  • Ler notícia

    September 1, 2012

    Newsletter 2012.08 – Expansion to the South of Brazil

    It is with great pleasure that we announce the opening of a new office and the admission of a new partner on September 1st.

    Our new office is located in Porto Alegre, the capital of the state of Rio Grande do Sul, in the South of Brazil. In the last decades, this region has attracted investments in all areas, which have fostered the growth of new technologies and the development of new businesses.

    We are honored to admit to our partnership, as head of the Porto Alegre Office, the renowned lawyer Fabiano de Bem da Rocha, born and raised in the South. Fabiano is a good friend of ours and a bright professional, who is widely admired in Brazil.

  • Kasznar Leonardos
  • Ler notícia

    August 2, 2012

    Newsletter 2012.07 – Coexistence agreements in Brazil

    After a long period of darkness on this subject, the BPTO has just released an official communication on how the Coexistence Agreements shall be treated. The former BPTO’s Guidelines for the Analysis of Trademarks (issued in May/1997) formally admitted that Coexistence Agreements excluded the application of the norm contained in Section 124, item XIX, of the Brazilian IP Law, which prohibits the registration of marks that are identical or similar to another previously registered for the same or related goods or services, being susceptible of causing confusion or association with the senior mark.

    Notwithstanding the fact that this guideline has lasted for over 13 years, it has always been refuted by the BPTO Attorneys’ Office, under the allegation that the Agreement by itself could never override that statutory prohibition. During the discussions for the revision of the BPTO’s Guidelines for the Analysis of Trademarks, which final version was released in December 2010, the BPTO Attorneys’ Office

    • ...
    Ler notícia

    August 1, 2012

    Newsletter 2012.06 – ANVISA’s role limited by Courts again

    After a long period of darkness on this subject, the BPTO has just released an official communication on how the Coexistence Agreements shall be treated. The former BPTO’s Guidelines for the Analysis of Trademarks (issued in May/1997) formally admitted that Coexistence Agreements excluded the application of the norm contained in Section 124, item XIX, of the Brazilian IP Law, which prohibits the registration of marks that are identical or similar to another previously registered for the same or related goods or services, being susceptible of causing confusion or association with the senior mark.

    Notwithstanding the fact that this guideline has lasted for over 13 years, it has always been refuted by the BPTO Attorneys’ Office, under the allegation that the Agreement by itself could never override that statutory prohibition. During the discussions for the revision of the BPTO’s Guidelines for the Analysis of Trademarks, which final version was released in December 2010, the BPTO Attorneys’ Office

  • Kasznar Leonardos
  • Ler notícia

    July 9, 2012

    Newsletter 2012.05 – Brazilian government enacts law creating generic veterinary medicinal products

    On 20 July 2012, Law No. 12,689, of 19 July 2012, was published in the Federal Official Gazette. This law seeks to create generic veterinary medicinal products in the country and to establish rules concerning the marketing authorisation of such products to be applied by the Ministry of Agriculture, Animal Husbandry and Supply (MAPA).

    In brief, two new categories of veterinary medicinal products have been created in addition to the existing reference veterinary drugs: similar (“branded generic”) and generic medicinal products for veterinary use.

    According to Law No. 12,689/12, a similar veterinary medicinal product shall mean a medicinal product which has the same active substance, the same concentration and pharmaceutical form as the reference medicinal product for veterinary use, but which excipients may or not be identical, always being identified by its trade mark. Law No. 12,689/12 has apparently not considered a similar veterinary medicinal product to be interchangeable with the re

  • Kasznar Leonardos
  • Ler notícia

    July 1, 2012

    Newsletter 2012.04 – Further information on ANVISA’s role

    Following our recent newsletter on ANVISA’s role in the examination of pharmaceutical patent applications, this is to briefly inform that the Brazilian PTO has started forwarding cases to ANVISA’s consent before substantive examination has begun, in accordance with the guidelines suggested by the Interministerial Working Group (GTI), through Ordinance No. 1,065, of 24 May 2012.

     

    Please note, however, that neither ANVISA nor the Brazilian PTO has yet issued normative acts indicating whether the GTI’s guidelines suggested would actually be adopted and, in the affirmative, to what extent. Yet, the Brazilian PTO has claimed, in the accompanying letters sent to ANVISA with patent applic

  • Kasznar Leonardos
  • Ler notícia